$IFRX almost seven months ago “InflaRx launches late-stage study of IFX-1 in COVID-19-induced pneumonia”. Now, still waiting for an update on the progress of this study. IMO there is no justification for not doing so, regardless of whether progress is slower than expected or the expected objectives are not being achieved. Transparency is essential for a good governance.
9
2
2 Likes